We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+33.56%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.42B
AUM Growth
+$877M
(+19%)
Cap. Flow
-$870M
Cap. Flow
% of AUM
-16.07%
Top 10 Holdings %
Top 10 Hldgs %
57.84%
Holding
236
New
154
Increased
21
Reduced
12
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oscar Health
OSCR
|
+$77.6M |
| 2 |
Baxter International
BAX
|
+$48.1M |
| 3 |
Revolution Medicines
RVMD
|
+$32.2M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$26.2M |
| 5 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$22.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$38.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$36M |
| 3 |
ACH
Accendra Health
ACH
|
+$21.8M |
| 4 |
MRUS
Merus
MRUS
|
+$20M |
| 5 |
Roivant Sciences
ROIV
|
+$18.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.17% |
| 2 | Technology | 0.1% |
| 3 | Industrials | 0.09% |
| 4 | Consumer Discretionary | 0.08% |
| 5 | Consumer Staples | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
The Oncology Institute
TOI
$519M
| $6.85M | 0.13% |
3,360,052
| – | – |
|
52
Cogent Biosciences
COGT
$6.91B
| $6.41M | 0.12% |
1,089,345
| – | – |
|
|
VIGL
53
DELISTED
Vigil Neuroscience
VIGL
| $3.97M | 0.07% |
1,173,523
-653,877
| -36% | -$3.36M |
|
54
Annexon
ANNX
$841M
| $2.65M | 0.05% |
583,913
| – | – |
|
|
OMIC
55
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $2.29M | 0.04% |
166,162
| – | – |
|
56
GeneDx Holdings
WGS
$1.8B
| $1.77M | 0.03% |
643,110
-610,785
| -49% | -$1.42M |
|
|
NYXH
57
Nyxoah
NYXH
$140M
| $811K | 0.02% |
174,842
-225,414
| -56% | -$1.24M |
|
58
Ramaco Resources Class A
METC
$664M
| $722K | 0.01% |
+43,433
| New | +$603K |
|
59
Mine Safety
MSA
$6.78B
| $673K | 0.01% |
+3,987
| New | +$648K |
|
60
Altria Group
MO
$122B
| $577K | 0.01% |
+14,296
| New | +$591K |
|
61
NVIDIA
NVDA
$4.76T
| $568K | 0.01% |
+11,460
| New | +$531K |
|
62
TriMas Corp
TRS
$1.45B
| $555K | 0.01% |
+21,896
| New | +$541K |
|
63
Pilgrim's Pride
PPC
$6.94B
| $552K | 0.01% |
+19,960
| New | +$508K |
|
|
AFIB
64
DELISTED
Acutus Medical Inc
AFIB
| $537K | 0.01% |
2,660,808
| – | – |
|
65
Johnson & Johnson
JNJ
$641B
| $510K | 0.01% |
+3,254
| New | +$499K |
|
66
Murphy Oil
MUR
$5.38B
| $496K | 0.01% |
+11,625
| New | +$509K |
|
67
Woodward
WWD
$25B
| $491K | 0.01% |
+3,610
| New | +$472K |
|
68
Andersons Inc
ANDE
$2.54B
| $490K | 0.01% |
+8,517
| New | +$442K |
|
69
Visteon
VC
$2.82B
| $475K | 0.01% |
+3,803
| New | +$470K |
|
70
KKR & Co
KKR
$91.3B
| $465K | 0.01% |
+5,610
| New | +$380K |
|
71
Leidos
LDOS
$14.5B
| $453K | 0.01% |
+4,182
| New | +$426K |
|
72
Mesa Laboratories
MLAB
$540M
| $452K | 0.01% |
+4,313
| New | +$420K |
|
73
DexCom
DXCM
$28.3B
| $452K | 0.01% |
+3,640
| New | +$372K |
|
74
Maximus
MMS
$3.2B
| $443K | 0.01% |
+5,277
| New | +$421K |
|
|
JNPR
75
DELISTED
Juniper Networks
JNPR
| $429K | 0.01% |
+14,540
| New | +$399K |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q4 2023 Portfolio in Review
As of Q4 2023, Deerfield Management held 236 positions worth $5.42B, up 19% from $4.54B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Deerfield Management withdrew a net $870M in Q4 2023, closing 14 positions and reducing 12 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $38.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 68% a quarter earlier, followed by Technology and Industrials.
Against the trend, Deerfield Management opened a new position in Oscar Health worth $103M.
- Deerfield Management's largest Q4 2023 buy was Oscar Health: 11,246,820 shares worth $103M.
- Deerfield Management added most to Revolution Medicines in Q4 2023, an estimated $32.2M increase.
- Deerfield Management's biggest Q4 2023 reduction was Neurocrine Biosciences, cutting an estimated $36M.
- Deerfield Management fully exited Intercept Pharmaceuticals, Inc. in Q4 2023, selling an estimated $38.5M.
- Deerfield Management's ten largest holdings make up 58% of its $5.42B portfolio in Q4 2023.
- Deerfield Management opened 154 new positions and closed 14 in Q4 2023.
- Deerfield Management's portfolio value rose 19% quarter-over-quarter to $5.42B.
Based on Deerfield Management's 13F filing for Q4 2023, filed 14 Feb 2024.